The clinical impact of macrolide resistance in pneumococcal respiratory infections

International Journal of Antimicrobial Agents

Volumn 18, Issue SUPPL.1, 2001, Pages 33-38

  Garau, J ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Community acquired pneumonia; Macrolide; Penicillin; Resistance; Streptococcus pneumoniae

Indexed keywords

ANTIINFECTIVE AGENT; MACROLIDE;

ANTIBIOTIC RESISTANCE; DRUG EFFECT; HEALTH SURVEY; HUMAN; MICROBIOLOGICAL EXAMINATION; MICROBIOLOGY; PENICILLIN RESISTANCE; PHYSIOLOGY; RESPIRATORY TRACT INFECTION; REVIEW; STREPTOCOCCUS INFECTION; STREPTOCOCCUS PNEUMONIAE;

ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, MICROBIAL; HUMANS; MACROLIDES; MICROBIAL SENSITIVITY TESTS; PENICILLIN RESISTANCE; PNEUMOCOCCAL INFECTIONS; POPULATION SURVEILLANCE; RESPIRATORY TRACT INFECTIONS; STREPTOCOCCUS PNEUMONIAE;

EID: 0002927225     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0924-8579(01)00394-6     Document Type: Article

References (49)

1. Haight TH, Finland M. Resistance of bacteria to erythromycin, Proc Soc Exp Biol Med 1952;81:183-88.
2. Francis RJ, May JR, Spicer CC. Influence of daily penicillin, tetracycline, erythromycin, and sulphamethoxypyridazine on exacerbations of bronchitis. Br Med J 1964;i:728.
3. Dixon JM. Pneumococcus resistant to erythromycin and lincomycin. Lancet 1967;i:573.
4. Erythromycin-resistant Streptococcus pneumonias. Lancet 1988;ii:1432-33.
5. Sanchez C, Armengol R, Lite J, Mir I, Garau J. Penicillin-resistant pneumococci and community-acquired pneumonia. Lancet 1992;239:988.
6. Lonks JR, Medeiros AA. High rate of erythromycin and clarithromycin resistance among Streptococcus pneumoniae isolates from blood cultures from Providence, R.I. Antimicrob Agents Chemother 1993;37:1742-5.
7. Moreno S, Garcia-Leoni ME, Cercenado E, et al. Infections caused by erythromycin-resistant Streptococcus pneumoniae: incidence, risk factors, and response to therapy in a prospective study. Clin Infect Dis 1995;20:1195-2000.
8. Jacobs MR. Emergence of antibiotic resistance in upper and lower respiratory tract infections. Am J Manag Care 1999;5(Suppl. 11):S651-61.
9. Rahav G, Toledano Y, Engelhard D, et al. Invasive pneumococcal infections. A comparison between adults and children. Medicine (Baltimore) 1997;76:295-303.
10. Marston B-J, Plouffe JF, File TM Jr, et al. Incidence of community-acquired pneumonia requiring hospitalization. Results of a population-based active surveillance Study in Ohio. Arch Intern Med 1997;157:1709-18.
11. Ruiz-Gonzalez A, Falguera M, Noges A, Rubio-Cabellero M. Is Streptococcus pneumoniae the leading cause of pneumonia of unknown etiology? A microbiologic study of lung aspirates in consecutive patients with community-acquired pneumonia. Am J Med 1999;106:385-90.
12. Hofmann J, Cetron MS, Farley MM, et al. The prevalence of drug-resistant Streptococcus pneumoniae in Atlanta. N. Engl J Med 1995;333:481-6.
13. Dellamonica P. Epidemiology of bacterial ENT and bronchopulmonary infection in 1998. Presse Med 1999;28(Suppl. 1):3-5.
14. Fine MJ, Smith MA, Carson CA, Mutha SS, Sankey SS, Kapoor WN. Prognosis and outcomes of patients with communityacquired pneumonia. J Am Med Assoc 1996;275:134-41.
15. Ortqvist A. Pneumococcal disease in Sweden: experiences and current situation. Am J Med 1999;107(Suppl. 1A):44S-9S.
16. Carratala J, Marron A, Fernandez-Sevilla A, Liñares J, Guidol F. Treatment of penicillin-resistant pneumococcal bacteremia in neutropenic patients with cancer. Clin Infect Dis 1997;24:148-52.
17. Finch RG, Woodhead MA. Practical considerations and guidelines for the management of community-acquired pneumonia. Drugs 1998;55:31-45.
18. National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial susceptibility testing. Sixth information supplement, M100-57. Villanova PA: National Committee for Clinical Laboratory Standards, 1997.
19. Craig WA. Pharmacokinetics/pharmacodynamic parameters rationale for antibiotic dosing of mice and men. Clin Infect Dis 1998;26:1-10.
20. Nightingale CH. Pharmacokinetics and pharmacodynamics of newer macrolides. Pediatr Infect Dis J 1997;16:438-43.
21. Thornsberry C, Sahm DF. Antimicrobial resistance in respiratory tract pathogens: results of an international surveillance study. Chemotherapy 2000;46(Suppl. 1):15-23.
22. Doern GV, Bruggemann AB, Huynh H, Wingert E. Antimicrobial resistance with Streptococcus pneumonias in the United States, 1997-98. Emerg Infect Dis 1999;5:757-65.
23. Felmingham D, Gruneberg RN. The Alexander Project 1996-1997: latest susceptibility data from this international study of bacterial pathogens from community-acquired lower respiratory tract infections. J Antimicrob Chemother 2000;45:191-203.
24. Doern GV, Pfaller MA, Kugler K, Freeman J, Jones RN. Prevalence of antimicrobial resistance among respiratory tract isolates of Streptococcus pneumoniae in North America. 1997 results from the SENTRY antimicrobial surveillance program. Clin Infect Dis 1998;27:464-70.
25. Pontani D, Washton H, Bouchillon S, Johnson J. Susceptibility of European respiratory tract isolates to trovafloxacin, ciprofloxacin, clarithromycin, azithromycin and ampicillin. Eur J Clin Microbiol Infect Dis 1998;17:413-9.
26. Nissinen A, Leinonen M, Huovinen P, et al. Antimicrobial resistance of Streptococcus pneumoniae in Finland, 1987-1990. Clin Infect Dis 1995;20:1275-80.
27. Hermans PW, Sluijter M, Elzenaar K, et al. Penicillin-resistant Streptococcus pneumoniae in The Netherlands: results of a 1-year molecular epidemiologic survey. J Infect Dis 1997;175:1413-22.
28. Fenoll A, Jado I, Vicioso D, Perez A, Casal J. Evolution of Streptococcus pneumoniae serotypes and antibiotic resistance in Spain: update (1990 to 1996). J Clin Microbiol 1998;36:3447-54.
29. Setchanova L, Tomasz A. Molecular characterization of penicillin-resistant Streptococcus pneumoniae isolates from Bulgaria. J Clin Microbiol 1999;37:638-48.
30. Tarasi A, Chong Y, Lee K, Tomasz A. Spread of the serotype 23F multidrug-resistant Streptococcus pneumoniae clone to South Korea. Microb Drug Resist 1997;3:105-9.
31. Tomasz A, Corso A, Severina EP, et al. Molecular epidemiologic characterization of penicillin-resistant Streptococcus pneumoniae invasive pediatric isolates recovered in six Latin-American countries: an overview. PAHO/Rockefeller University Workshop. Pan American Health Organization. Microb Drug Resist 1998;4:195-207.
32. Zhanel GG, Karlowsky JA, Palatnick L, et al. Prevalence of antimicrobial resistance in respiratory tract isolates of Streptococcus pneumoniae: results of a Canadian national surveillance study. Antimicrob Agents Chemother 1999;43:2504-9.
33. Appelbaum PC. Antimicrobial resistance in Streptococcus pneumoniae: an overview. Clin Infect Dis 1992;15:77-83.
34. Koornhof HJ, Wasas A, Klugman K. Antimicrobial resistance in Streptococcus pneumoniae: a South African perspective. Clin Infect Dis 1992;15:84-94.
35. Wang EE, Kellner JD, Arnold S. Antibiotic-resistant Streptococcus pneumoniae. Implications for medical practice. Can Fam Physician 1998;44:1881-8.
36. Garcia-Leoni ME, Cercenado E, Rodeno P, Bernaldo de Quiros JC, Martinez-Hernandez D, Bouza E. Susceptibility of Streptococcus pneumoniae to penicillin: a prospective microbiological and clinical study. Clin Infect Dis 1992;14:427-35.
37. Crook DW, Spratl BG. Multiple antibiotic resistance in Streptococcus pneumoniae. Br Med Bull 1998;54:595-610.
38. Jacobs MR, Bajaksouzian S, Zilles A, Lin G, Pankuch GA, Appelbaum PC. Susceptibilities of Streptococcus pneumoniae and Haemophilus influenzae to 10 oral antimicrobial agents based on pharmacodynamic parameters: 1997 U.S. Surveillance study. Antimicrob Agents Chemother 1999;43:1901-8.
39. Thornsberry C, Jones ME, Hickey ML, Mauriz Y, Kahn J, Sahm DF. Resistance surveillance of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis isolated in the United States, 1997-1998. J Antimicrob Chemother 1999;44:749-59.
40. Hsueh PR, Teng LJ, Lee LN, Yang PC, Ho SW, Luh KT. Extremely high incidence of macrolide and trimethoprim-sulfamethoxazole resistance among clinical isolates of Streptococcus pneumoniae in Taiwan. J Clin Microbiol 1999;37:893-901.
41. Pechère PC. Macrolide resistance mechanisms in Gram-positive cocci. Int J Antimicrob Agents 2001;18(Suppl. 1):25-8.
42. Craft JC, Notario G, Hom R, Shortridge D, Flamm RK, Can erythromycin resistant Streptococcus pneumoniae be treated with a macrolide. Poster presented at Fifth International Conference on the Macrolides, Azalides, Streptogramins, Ketolides and Oxazolidinones, 2000. Abstract no. 7.04.
43. Reid R Jr, Bradley JS, Hindler J. Pneumococcal meningitis during therapy of otitis media with clarithromycin. Pediatr Infect Dis J 1995;14:1104-5.
44. Jackson MA, Barry VF, Olson LC, Duthie SE, Kearns GL. Breakthrough sepsis in macrolide-resistant pneumococcal infection. Pediatr Infect Dis J 1996;15:1049-51.
45. Fogarty C, Goldschmidt R, Bush K. Bacteremic pneumococcal pneumonia due to multi-drug resistant pneumococci in three patients treated unsuccessfully with azithromycin and successfully with levofloxacin. Clin Infect Dis 2000;31:613-15.
46. Kelley MA, Weber DJ, Gilligan P, Cohen MS. Breakthrough bacteremia in patients being treated with azithromycin and clarithromycin. Clin Infect Dis 2000;31:1008-11.
47. Waterer GW, Wunderink RG. Fatal pneumococcal pneumonia attributed to macrolide resistance and azithromycin monotherapy. Chest 2000;118:1839-40.
48. Garau J, Lonks JR, Gomez L, Xercavins M, Medeiros AA. Failure of macrolide therapy in patients with bacteremia due to macrolide resistant Streptococcus pneumonias. Fifth International Conference on the Macrolides, Azalides, Streptogramins, Ketolides and Oxazolidinones, 2000. Abstract no. 7.09.
49. Dagan R, Abramson O, Leibovitz E, et al. Bacteriologic response to oral cephalosporins: are established susceptibility breakpoints appropriate in the case of acute otitis media? J Infect Dis 1997;176:1253-9.